{"id":"bv100-300-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benzoxaboroles are a novel class of boron-containing compounds that bind to the editing site of leucyl-tRNA synthetase, preventing the aminoacylation of tRNA and thus blocking bacterial protein synthesis. This mechanism is distinct from conventional antibiotics and may provide activity against drug-resistant organisms. BV100 is being developed for serious bacterial infections, particularly those caused by resistant gram-negative pathogens.","oneSentence":"BV100 is a benzoxaborole antibiotic that inhibits bacterial leucyl-tRNA synthetase, disrupting protein synthesis in susceptible pathogens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:04:40.621Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections caused by resistant gram-negative organisms (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07431307","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-07","conditions":"Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection","enrollment":120},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT05685615","phase":"PHASE2","title":"PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2023-04-20","conditions":"Ventilator Associated Pneumonia","enrollment":39},{"nctId":"NCT05684718","phase":"PHASE1","title":"To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2023-02-01","conditions":"Bacterial Infections","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rifabutin for Infusion"],"phase":"phase_3","status":"active","brandName":"BV100 (300 mg)","genericName":"BV100 (300 mg)","companyName":"BioVersys SAS","companyId":"bioversys-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BV100 is a small molecule (modality) with the synonym MG-S-2525, used in clinical trials for various bacterial infections, including Ventilator Associated Pneumonia, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Blood Stream Infection, and Meningitis. It has been studied in combination with other antibiotics, such as polymyxin B and ceftazidime/avibactam, in clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}